ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2019; 10(7):1675-1684. doi:10.7150/jca.29993 This issue Cite
Review
Multiple Myeloma: What Do We Do About Immunodeficiency?
1. Second Clinical Medical College, Southern Medical University, Guangzhou, China.
2. Department of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China.
Citation:
Li L, Wang L. Multiple Myeloma: What Do We Do About Immunodeficiency?. J Cancer 2019; 10(7):1675-1684. doi:10.7150/jca.29993. https://www.jcancer.org/v10p1675.htm
Other stylesAbstract
Multiple myeloma (MM) is an incurable hematological malignancy. Immunodeficiency results in the incapability of immunity to eradicate both tumor cells and pathogens. Immunotherapies along with antibiotics and other anti-infectious agents are applied as substitutes for immunity in MM. Immunotherapies including monoclonal antibodies, immune checkpoints inhibitors, affinity- enhanced T cells, chimeric antigen receptor T cells and dendritic cell vaccines are revolutionizing MM treatment. By suppressing the pro-inflammatory milieu and pathogens, prophylactic and therapeutic antibiotics represent anti-tumor and anti-infection properties. It is expected that deeper understanding of infection, immunity and tumor physio-pathologies in MM will accelerate the optimization of combined therapies, thus improving prognosis in MM.
Keywords: immunodeficiency, multiple myeloma, immunotherapy, antibiotic
Citation styles
APA
Li, L., Wang, L. (2019). Multiple Myeloma: What Do We Do About Immunodeficiency?. Journal of Cancer, 10(7), 1675-1684. https://doi.org/10.7150/jca.29993.
ACS
Li, L.; Wang, L. Multiple Myeloma: What Do We Do About Immunodeficiency?. J. Cancer 2019, 10 (7), 1675-1684. DOI: 10.7150/jca.29993.
NLM
Li L, Wang L. Multiple Myeloma: What Do We Do About Immunodeficiency?. J Cancer 2019; 10(7):1675-1684. doi:10.7150/jca.29993. https://www.jcancer.org/v10p1675.htm
CSE
Li L, Wang L. 2019. Multiple Myeloma: What Do We Do About Immunodeficiency?. J Cancer. 10(7):1675-1684.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.